Should I buy or sell Alimera Sciences stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALIM shares. View ALIM analyst ratings or view top-rated stocks .

What is Alimera Sciences' stock price target for 2024?

3 Wall Street analysts have issued 1-year price targets for Alimera Sciences' shares. Their ALIM share price targets range from $5.00 to $10.00. On average, they expect the company's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 118.0% from the stock's current price. View analysts price targets for ALIM or view top-rated stocks among Wall Street analysts .

How have ALIM shares performed in 2024?

Alimera Sciences' stock was trading at $4.32 at the start of the year. Since then, ALIM stock has decreased by 20.4% and is now trading at $3.44. View the best growth stocks for 2024 here .

Are investors shorting Alimera Sciences?

Alimera Sciences saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 108,800 shares, an increase of 26.8% from the March 15th total of 85,800 shares. Based on an average daily volume of 81,900 shares, the days-to-cover ratio is presently 1.3 days. View Alimera Sciences' Short Interest .

When is Alimera Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ALIM earnings forecast .

How were Alimera Sciences' earnings last quarter?

Alimera Sciences, Inc. (NASDAQ:ALIM) announced its quarterly earnings results on Thursday, March, 7th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by $0.09. The biopharmaceutical company earned $26.31 million during the quarter, compared to the consensus estimate of $25.10 million. Alimera Sciences had a negative trailing twelve-month return on equity of 130.90% and a negative net margin of 24.93%. During the same period in the prior year, the firm earned ($0.54) earnings per share.

When did Alimera Sciences' stock split?

Shares of Alimera Sciences reverse split on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What guidance has Alimera Sciences issued on next quarter's earnings?

Alimera Sciences issued an update on its FY 2024 earnings guidance on Thursday, March, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $105.0 million-, compared to the consensus revenue estimate of $103.7 million.

What is Rick Eiswirth's approval rating as Alimera Sciences' CEO?

2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com . Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alimera Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT) , OPKO Health (OPK) , VBI Vaccines (VBIV) , Aldeyra Therapeutics (ALDX) , Advanced Micro Devices (AMD) , Amarin (AMRN) , AngloGold Ashanti (AU) , SSR Mining (SSRM) , ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB) .

How do I buy shares of Alimera Sciences?

Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ALIM

Alimera Sciences (ALIM) Stock Price, News & Analysis

→ Don’t expose yourself to stocks during the week (From DTI) (Ad)

Free ALIM Stock Alerts

$3.44

-0.11 (-3.10%)

(As of 04/18/2024 ET)

Compare

Today's Range: $3.27
▼
$3.66
50-Day Range: $3.25
▼
$4.21
52-Week Range: $1.56
▼
$4.38

Volume: 56,731 shs
Average Volume: 78,484 shs
Market Capitalization: $180.08 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.50

Get Alimera Sciences alerts:

Alimera Sciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 118.0% Upside
$7.50 Price Target
Short Interest: Healthy
0.21% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.76
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.67 out of 5 stars

Medical Sector

417th out of 918 stocks

Pharmaceutical Preparations Industry

179th out of 402 stocks

3.5

Analyst's Opinion

Consensus Rating
Alimera Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Alimera Sciences has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.21% of the outstanding shares of Alimera Sciences have been sold short.
Short Interest Ratio / Days to Cover
Alimera Sciences has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Alimera Sciences has recently increased by 26.81%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Alimera Sciences does not currently pay a dividend.
Dividend Growth
Alimera Sciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ALIM.

3.2

News and Social Media Coverage

News Sentiment
Alimera Sciences has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Alimera Sciences this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for ALIM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
5 people have added Alimera Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alimera Sciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
31.40% of the stock of Alimera Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
99.83% of the stock of Alimera Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Alimera Sciences is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Alimera Sciences is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Alimera Sciences has a P/B Ratio of 3.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Alimera Sciences Stock (NASDAQ:ALIM)

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

ALIM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALIM Stock News Headlines

April 14, 2024 | americanbankingnews.com

Alimera Sciences (NASDAQ:ALIM) Downgraded by StockNews.com to Hold

April 3, 2024 | finance.yahoo.com

Luckie & Company Acquires Marbury Creative Group

April 18, 2024 | DTI (Ad)

Don’t expose yourself to stocks during the week

The S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.

April 3, 2024 | bizjournals.com

Luckie & Co. acquires Atlanta marketing agency

March 26, 2024 | finance.yahoo.com

Ocular Inflammation Treatment Market InsightAce Exclusive Report 2024-2031

March 20, 2024 | finance.yahoo.com

Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 19, 2024 | finanznachrichten.de

Alimera Sciences, Inc.: Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network

March 19, 2024 | finance.yahoo.com

Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network

April 18, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 19, 2024 | globenewswire.com

Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network

March 18, 2024 | msn.com

Mizuho downgrades Amylyx to Neutral after ALS trial setback

March 10, 2024 | realmoney.thestreet.com

Alimera Sciences price target raised by $1 at H.C. Wainwright, here's why

March 9, 2024 | seekingalpha.com

Alimera Sciences, Inc. (ALIM) Q4 2023 Earnings Call Transcript

March 8, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Alimera Sciences Amid Strong Financial Performance and Promising Clinical Trials

March 8, 2024 | finance.yahoo.com

Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2023 Earnings Call Transcript

March 8, 2024 | finance.yahoo.com

Q4 2023 Alimera Sciences Inc Earnings Call

March 7, 2024 | investorplace.com

ALIM Stock Earnings: Alimera Sciences Beats Revenue for Q4 2023

March 7, 2024 | finanznachrichten.de

Alimera Sciences, Inc.: Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results

March 7, 2024 | globenewswire.com

Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results

March 6, 2024 | benzinga.com

A Preview Of Alimera Sciences's Earnings

March 6, 2024 | finance.yahoo.com

Alimera Sciences, Inc. (NASDAQ:ALIM) Has Found A Path To Profitability

February 29, 2024 | finance.yahoo.com

Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update

February 10, 2024 | msn.com

Alimera Sciences Launches 2024 Equity Inducement Plan

February 8, 2024 | finance.yahoo.com

The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®

January 25, 2024 | finance.yahoo.com

Alimera Sciences (NASDAQ:ALIM) shareholders have endured a 69% loss from investing in the stock five years ago

January 4, 2024 | finance.yahoo.com

Alimera Completes Recruitment for the Synchronicity Study

January 2, 2024 | marketwatch.com

Alimera Sciences Names Elliot Maltz Chief Financial Officer

See More Headlines

Receive ALIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ALIM
CUSIP: N/A
CIK: 1267602
Web: www.alimerasciences.com
Phone: (678) 990-5740
Fax: 678-990-5744
Employees: 154
Year Founded: 2003

Price Target and Rating

Average Stock Price Target: $7.50
High Stock Price Target: $10.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +118.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.16)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 114.67
P/E Growth: N/A
Net Income: $-20,130,000.00
Net Margins: -24.93%
Pretax Margin: -24.83%
Return on Equity: -130.90%
Return on Assets: -10.22%

Debt

Debt-to-Equity Ratio: 1.40
Current Ratio: 2.39
Quick Ratio: 2.31

Sales & Book Value

Annual Sales: $80.75 million
Price / Sales: 2.23
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.88 per share
Price / Book: 3.91

Miscellaneous

Outstanding Shares: 52,350,000
Free Float: 35,915,000
Market Cap: $180.08 million
Optionable: Optionable
Beta: 1.18

Social Links

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Richard S. Eiswirth Jr. (Age 56)
CEO & Director
Comp: $597.87k
Mr. David R. Holland (Age 60)
Co-Founder, Chief Marketing Officer and Senior VP of Corporate Communications & Managed Markets
Comp: $413.5k
Dr. Philip Ashman Ph.D. (Age 59)
President of International Operations
Comp: $389.86k
Mr. Todd Michael Wood (Age 54)
President of U.S. Operations
Mr. Elliot Maltz CPA (Age 39)
CFO & Treasurer
Mr. Jason Werner
Chief Operating Officer
Christopher S. Visick
VP, General Counsel & Secretary
Dr. David Dyer M.D.
Chief Retina Specialist

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALIM Stock Analysis - Frequently Asked Questions

Should I buy or sell Alimera Sciences stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALIM shares.
View ALIM analyst ratings or view top-rated stocks.
What is Alimera Sciences' stock price target for 2024?: 3 Wall Street analysts have issued 1-year price targets for Alimera Sciences' shares. Their ALIM share price targets range from $5.00 to $10.00. On average, they expect the company's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 118.0% from the stock's current price.
View analysts price targets for ALIM or view top-rated stocks among Wall Street analysts.
How have ALIM shares performed in 2024?: Alimera Sciences' stock was trading at $4.32 at the start of the year. Since then, ALIM stock has decreased by 20.4% and is now trading at $3.44.
View the best growth stocks for 2024 here.
Are investors shorting Alimera Sciences?: Alimera Sciences saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 108,800 shares, an increase of 26.8% from the March 15th total of 85,800 shares. Based on an average daily volume of 81,900 shares, the days-to-cover ratio is presently 1.3 days.
View Alimera Sciences' Short Interest.
When is Alimera Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ALIM earnings forecast.
How were Alimera Sciences' earnings last quarter?: Alimera Sciences, Inc. (NASDAQ:ALIM) announced its quarterly earnings results on Thursday, March, 7th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by $0.09. The biopharmaceutical company earned $26.31 million during the quarter, compared to the consensus estimate of $25.10 million. Alimera Sciences had a negative trailing twelve-month return on equity of 130.90% and a negative net margin of 24.93%. During the same period in the prior year, the firm earned ($0.54) earnings per share.

When did Alimera Sciences' stock split?: Shares of Alimera Sciences reverse split on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What guidance has Alimera Sciences issued on next quarter's earnings?: Alimera Sciences issued an update on its FY 2024 earnings guidance on Thursday, March, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $105.0 million-, compared to the consensus revenue estimate of $103.7 million.
What is Rick Eiswirth's approval rating as Alimera Sciences' CEO?: 2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Alimera Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB).
How do I buy shares of Alimera Sciences?: Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALIM) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial